mRNA Vaccines in Infectious Diseases Market Outlook and Trends by Opportunities, Challenges, Unmet Needs, and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

mRNA Vaccines in Infectious Diseases Market Report Overview

The first mRNA vaccines for COVID-19 gained authorization for use in December 2020. These vaccines have been proven highly successful clinically and commercially, dominating the COVID-19 vaccine market. Furthermore, the success of the COVID-19 mRNA vaccines has renewed interest in mRNA vaccines for a variety of other infectious diseases such as influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), Mpox, herpes, Zika virus, and Lyme disease. The report provides an assessment of the mRNA vaccines space, including the history of mRNA Therapeutics Development, industry trends, marketed products, pipeline products, opportunities, challenges, and unmet needs, current companies, and a brief market outlook.

Messenger RNA (mRNA) is a single-stranded ribonucleic acid that is transcribed from a strand of DNA. mRNA carries the coding information for protein synthesis. mRNA vaccines use mRNA that corresponds to a viral protein, such as a small piece of protein found on the outer membrane, to induce an immune response. The body produces spike proteins triggered by the mRNA, which look like the antigens of the viral protein.

Key Marketed Products ·        Comirnaty (BNT162b2/tozinameran)

·        Spikevax (mRNA-1273)

·        Nuvaxovid XBB.1.5

·        Gemcovac-19

·        AWcorna (Walvax)

·        Daichirona (DS-5670)

Key Pipeline Products ·        ARCT-2301

·        DS-5670b

·        BNT-162b5

·        LVRNA-009

·        mRNA-1283

Key Companies ·        Moderna

·        BioNTech

·        Pfizer

·        Arcturus Therapeutics

·        AIM Vaccine Co Ltd

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

mRNA Vaccines in Infectious Diseases Market by Marketed Products

The rapid sequencing of the SARS-CoV-2 viral genome and the subsequent development of mRNA vaccines in response to the COVID-19 pandemic occurred at unprecedented speed and marked a critical milestone in vaccinology. The mRNA vaccines for COVID-19 are dominating the COVID-19 vaccine market owing to its clinical and commercial success. Revenues for mRNA COVID-19 vaccines peaked in 2022, with Moderna’s Spikevax and Pfizer and BioNTech’s Comirnaty generating around $18.4 billion and $42.4 billion in global revenues in the same year.

The key market products in the mRNA vaccines in the infectious diseases market are Comirnaty (BNT162b2/tozinameran), Spikevax (mRNA-1273), Nuvaxovid XBB.1.5, Gemcovac-19, AWcorna (Walvax), and Daichirona (DS-5670) among others.

Spikevax (mRNA-1273): The product demonstrates the potential of Moderna’s broad mRNA vaccine platform. Furthermore, it offers the potential for booster dose label expansions.

Key Marketed Products for mRNA Vaccines in the Infectious Diseases Market

Key Marketed Products for mRNA Vaccines in the Infectious Diseases Market

Buy the Full Report for Additional Insights on the Key Marketed Products for mRNA Vaccines in the Infectious Diseases Market, Download a Free Sample Report

mRNA Vaccines in Infectious Diseases Market by Pipeline Products

The key pipeline products for mRNA vaccines in the infectious diseases market are ARCT-2301, DS-5670b, BNT-162b5, LVRNA-009, and mRNA-1283 among others. These pipeline products are classified based on various therapy areas including the COVID-19 pipeline, Influenza pipeline, RSV pipeline, combination pipeline, Lyme disease pipeline, Herpes pipeline, and Zika pipeline among others.

ARCT-2301: Meiji Seika is one of the largest Japanese pharma companies in infectious diseases. Therefore, the partnership between Arcturus and Meiji will help increase vaccine marketing. Arcturus Therapeutics already has another COVID-19 vaccine, ARCT-154, approved for use in the Japanese market.

Key Pipeline Products for mRNA Vaccines in the Infectious Diseases Market

Key Pipeline Products for mRNA Vaccines in the Infectious Diseases Market

Buy the Full Report for Additional Insights on the Key Pipeline Products for mRNA Vaccines in the Infectious Diseases Market, Download a Free Sample Report

mRNA Vaccines in Infectious Diseases Market – Competitive Landscape

The key companies in the mRNA vaccines in the infectious diseases market are Moderna, BioNTech, Pfizer, Arcturus Therapeutics, and AIM Vaccine Co Ltd among others. Moderna is the leading player within the pipeline landscape and is the only company investigating mRNA vaccines in a wide range of indications. Moderna’s mRNA-1345 vaccine for RSV and mRNA-1647 vaccine for CMV are projected to generate global revenues of $1.6 billion and $1.3 billion, respectively, by 2029.

Leading Companies in the mRNA Vaccines in Infectious Diseases Market

Leading Companies in the mRNA Vaccines in Infectious Diseases Market

Buy the Full Report for More Company-Wise Insights into the mRNA Vaccines in Infectious Diseases Market, Download a Free Sample Report

Scope

  • Overview of mRNA vaccinations and history of their therapeutics development.
  • Current global industry trends together with their opportunities and challenges.
  • Overview of currently marketed products within the global scope.
  • Global pipeline analysis.
  • Overview of leading companies within mRNA vaccines space.
  • Brief market overview for major mRNA vaccines products.

Key Highlights

• Report deliverables in a form of PowerPoint report

• Global scope of marketed and pipeline products

Reasons to Buy

  • Understand the trends shaping and driving the mRNA vaccines market.
  • Identify the innovative technologies and key players leading the mRNA vaccines field.
  • Recognize gaps and areas of unmet need within the mRNA vaccines market.
  • Determine the current and outlook for mRNA vaccines according to key opinion leaders (KOLs).

Moderna
BioNTech
Pfizer
Arcturus Therapeutics
AIM Vaccine Co Ltd
GSK
Sanofi
Novavax
CSPC Pharmaceutical
Gennova Biopharmaceutical
Walvax Biotechnology
Daiichi Sankyo
CSL
Suzhou Abogen

Table of Contents

01. Executive Summary

02. mRNA Vaccines Overview

03. Industry Trends

04. Marketed Products

05. Pipeline Products

06. Opportunities and Challenges

07. Companies

08. Market Outlook and Deals

09. Appendix

Frequently asked questions

mRNA Vaccines in Infectious Diseases Market Outlook and Trends by Opportunities, Challenges, Unmet Needs, and Competitive Landscape standard reports
Currency USD
$995

Can be used by individual purchaser only

$1,990

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

mRNA Vaccines in Infectious Diseases Market Outlook and Trends by Opportunities, Challenges, Unmet Needs, and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Venture Capital Investment Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Merger and Acquisition Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Emerging Market Outsourcing Report, Q2 2026
$2,950 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at mRNA Vaccines in Infectious Diseases Market Outlook and Trends by Opportunities, Challenges, Unmet Needs, and Competitive Landscape in real time.

  • Access a live mRNA Vaccines in Infectious Diseases Market Outlook and Trends by Opportunities, Challenges, Unmet Needs, and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.